| Population 2013 |
<1 million |
| |
| | | | | |
| Estimates of TB burden * 2013 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
<0.01 |
(<0.01–<0.01) |
0.19 |
(0.14–0.24) |
| Mortality (HIV+TB only) |
0 |
(–) |
0 |
(–) |
| Prevalence (includes HIV+TB) |
0.16 |
(0.061–0.29) |
25 |
(9.8–47) |
| Incidence (includes HIV+TB) |
0.13 |
(0.11–0.13) |
21 |
(18–22) |
| Incidence (HIV+TB only) |
<0.01 |
(<0.01–<0.01) |
0.42 |
(0.37–0.44) |
| Case detection, all forms (%) |
93 |
(89–110) |
|
|
| |
| | | | | |
| Estimates of MDR-TB burden * 2013 |
|
New |
|
Retreatment |
| % of TB cases with MDR-TB |
0 |
(0–5.4) |
0 |
(0–52) |
MDR-TB cases among notified pulmonary
TB cases |
0 |
(0–6) |
0 |
(0–5) |
| |
| | | | | |
| TB case notifications 2013 |
New ** |
Relapse |
| Pulmonary, bacteriologically confirmed |
67 |
|
5 |
| Pulmonary, clinically diagnosed |
36 |
|
3 |
| Extrapulmonary |
8 |
|
0 |
| |
|
|
|
| Total new and relapse |
119 |
|
|
| Previously treated, excluding relapses |
1 |
|
|
| Total cases notified |
120 |
|
|
| |
| | | | | |
| Among 119 new and relapse cases: | | | | | |
| 1 (<1%) cases aged under 15 years; male:female ratio: 1.6 | | | |
| | | | | |
| Reported cases of RR-/MDR-TB 2013 |
New |
Retreatment |
Total ** |
| Cases tested for RR-/MDR-TB |
67 (100%) |
5 (56%) |
72 |
| Laboratory-confirmed RR-/MDR-TB cases |
|
|
0 |
| Patients started on MDR-TB treatment |
|
|
0 |
| |
| | | | | |
| TB/HIV 2013 |
Number |
(%) |
| TB patients with known HIV status |
98 |
(82) |
| HIV-positive TB patients |
2 |
(2) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
0 |
(0) |
| HIV-positive TB patients on antiretroviral therapy (ART) |
2 |
(100) |
| HIV-positive people screened for TB |
|
|
| HIV-positive people provided with IPT |
|
|
| |
| | | | | |
| Treatment success rate |
(%) |
| New and relapse cases registered in 2012 |
84 |
| Previously treated cases, excluding relapse, registered in 2012 |
|
| HIV-positive TB cases, all types, registered in 2012 |
|
| RR-/MDR-TB cases started on second-line treatment in 2011 |
0 |
| XDR-TB cases started on second-line treatment in 2011 |
0 |
| |
| | | | | |
| Laboratories 2013 |
|
| Smear (per 100 000 population) |
0.2 |
| Culture (per 5 million population) |
8.0 |
| Drug susceptibility testing (per 5 million population) |
8.0 |
| Sites performing Xpert MTB/RIF |
0 |
| Is second-line drug susceptibility testing available? |
Yes, outside
country |
| |
| | | | | |
| Financing TB control 2014 |
|
| National TB programme budget (US$ millions) |
<1 |
| % Funded domestically |
31% |
| % Funded internationally |
8% |
| % Unfunded |
62% |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | |
| ** Includes cases with unknown previous TB treatment history | | |
| | | | | |